Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to at Oppenheimer

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective raised by equities researchers at Oppenheimer from to in a report released on Tuesday, The Fly reports.

TNDM has been the topic of a number of other reports. Cowen reissued an “outperform” rating and issued a $90.00 price objective (up from $85.00) on shares of Tandem Diabetes Care in a research report on Tuesday. Robert W. Baird downgraded shares of Tandem Diabetes Care from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $71.00 to $75.00 in a research report on Tuesday, February 4th. Stifel Nicolaus increased their price objective on shares of Tandem Diabetes Care from $70.00 to $77.00 and gave the company a “hold” rating in a research report on Tuesday. Raymond James increased their price objective on shares of Tandem Diabetes Care from $85.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, ValuEngine raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Tandem Diabetes Care has an average rating of “Buy” and an average target price of $83.60.

Shares of NASDAQ:TNDM opened at $76.53 on Tuesday. Tandem Diabetes Care has a 52 week low of $51.37 and a 52 week high of $91.65. The company’s 50 day moving average is $75.50 and its two-hundred day moving average is $65.85. The company has a current ratio of 2.78, a quick ratio of 2.05 and a debt-to-equity ratio of 0.07. The company has a market cap of $4.66 billion, a PE ratio of -159.43 and a beta of 0.08.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Monday, February 24th. The medical device company reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.07. Tandem Diabetes Care had a negative net margin of 6.83% and a negative return on equity of 8.99%. The company had revenue of $108.40 million for the quarter, compared to the consensus estimate of $109.22 million. During the same period in the prior year, the firm posted $0.02 EPS. The company’s quarterly revenue was up 42.3% compared to the same quarter last year. As a group, equities research analysts expect that Tandem Diabetes Care will post 0.04 EPS for the current year.

In related news, Chairman Kim D. Blickenstaff sold 50,000 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $75.92, for a total value of $3,796,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Brian B. Hansen sold 20,945 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $77.62, for a total transaction of $1,625,750.90. Following the completion of the transaction, the executive vice president now directly owns 7,046 shares in the company, valued at $546,910.52. The disclosure for this sale can be found here. Insiders sold a total of 299,316 shares of company stock worth $19,481,161 over the last ninety days. Insiders own 6.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC grew its position in shares of Tandem Diabetes Care by 393.5% in the 4th quarter. CWM LLC now owns 528 shares of the medical device company’s stock valued at $31,000 after buying an additional 421 shares during the last quarter. First Quadrant L P CA purchased a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at $34,000. TRUE Private Wealth Advisors purchased a new position in shares of Tandem Diabetes Care in the 4th quarter valued at $45,000. Sowell Financial Services LLC purchased a new position in shares of Tandem Diabetes Care in the 4th quarter valued at $54,000. Finally, US Bancorp DE grew its position in shares of Tandem Diabetes Care by 101.0% in the 4th quarter. US Bancorp DE now owns 1,164 shares of the medical device company’s stock valued at $70,000 after buying an additional 585 shares during the last quarter. 91.09% of the stock is currently owned by hedge funds and other institutional investors.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: Swap

The Fly

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.